Are administered treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intent
Participation in another therapeutic clinical study or receiving any investigational agent within  days of enrollment or during this clinical study
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent
Participated in a therapeutic clinical study within  weeks before study drug treatment, or current participation in other therapeutic investigational procedures.
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days or five half-lives of the drug prior to enrollment
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within  days prior to randomization
Patients who participated in any therapeutic clinical study with an investigational agent within the last  days
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days prior to enrollment
Participation in an investigational therapeutic drug trial within  days of study entry
Patients treated on any other therapeutic clinical protocols within  days prior to registration or during participation in the study
Participated in a therapeutic clinical study within  weeks before study drug treatment, or current participation in other therapeutic investigational procedures.
Patients treated on any other therapeutic clinical protocols within  days prior to study entry or during participation in the study
Patients treated on any other therapeutic clinical protocols within  weeks of registration
Patients treated on any other therapeutic clinical protocols within  days prior to study entry or during participation in the study
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within  days prior to Cycle  Day . For Phase b, participants who have received the following prior antitumor therapy: received nitrosoureas and mitomycin C within  weeks
Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within  days prior to start of this study
Treatment with any anticancer therapy or participation in another therapeutic clinical study with investigational drugs </= days (</= days for patients in Korea) prior to first dose of FPA
Concurrent participation in an investigational drug trial with therapeutic intent
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days prior to enrollment
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days prior to enrollment
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days prior to enrollment
Participation in an investigational therapeutic drug trial within  days of study entry
Patients who have participated in any therapeutic clinical study/received any investigational agent within the last  days are excluded from participation in this trial.
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  weeks prior to the first dose of study treatment
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days prior to enrollment; the following exceptions are allowed:\r\n* Unapproved/ experimental TKIs discontinued  days prior to cycle , day 
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within  days prior to Day  of Cycle
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within  days prior to enrollment
Patients treated on any other therapeutic clinical protocols within  days prior to study entry or during participation in the study
Use of an investigational therapeutic within  days
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within  days prior to enrolment
